Overview

Sorafenib in Urothelium Cancer of Bladder

Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the use of Sorafenib additionally to gemcitabine and cisplatin in bladder cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Association of Urogenital Oncology (AUO)
Association of Urologic Oncology (AUO)
Collaborator:
University Hospital, Essen
Treatments:
Niacinamide
Sorafenib